The SmithRx Broker Brief Newsletter

Discover 7 key lessons from industry leaders like Mark Cuban, Dr. Avantika Waring, and SmithRx CEO Jake Frenz on how employers can challenge legacy PBMs, reduce costs, and improve transparency in pharmacy benefits.

We are approaching the last quarter of the year which means renewal season for many self-funded employers.

“Fiduciary-aligned” is in almost every PBM proposal. Here’s how plan sponsors can test the claim.

Every PBM in your RFP may call itself transparent or pass-through. Here's how to test a modern PBM's contract, data access, and clinical execution before you sign.

Hear how SmithRx rebuilt the PBM model for full transparency—no spread pricing, no rebate games, just clear costs and aligned incentives.

Compare true vs. “fake” pass-through PBMs across 6 pillars to spot hidden costs and opaque practices.

SmithRx experts answer six questions from benefits leaders on rebate visibility, switching PBMs, AI, and GLP-1s.

We have previously discussed the standard methods used to evaluate PBMs and how contract definitions can impact PBM accountability in complex ways.

Discover six crucial areas where modern PBMs are redefining the industry, offering insights into how these innovations are creating more transparent, efficient, and client-focused pharmacy benefit solutions.

The administrative fee is easy to find in a PBM bid, but its amount alone doesn't show what your plan will pay. See how fee structures work, what else PBMs earn, and how to compare bids on total cost.

Members already in treatment show whether a PBM's transition support actually works. Here's how a PBM can support smooth approvals, refills, and specialty therapy carry over at go-live.

Traditional PBM market checks need an upgrade. Learn how updated analyses help employers hold PBMs accountable and satisfy fiduciary duties.